Raptor Pharmaceutical Licenses Intellectual Property for Rett Syndrome

Raptor Pharmaceutical Corp. (NASDAQ: RPTP ) announced that it has licensed pending patents related to the use of cysteamine for the treatment of Rett syndrome and associated disorders of methyl-CpG binding protein 2 (MECP2). Under terms of the agreement, Raptor receives exclusive global rights to develop and commercialize cysteamine